DOV PHARMACEUTICAL REPORTS RESULTS FROM BICIFADINE TRIAL

A A

DOV Pharmaceutical is conducting its first long term Phase III pivotal trial of bicifadine in chronic low back pain (CLBP). The trial is a multicenter, double-blind study comparing three dose regimens of bicifadine to placebo administered for three months to patients with CLBP.

The analysis of data on the improvement in pain scores from baseline to end of treatment -- the primary endpoint of the trial -- indicates that bicifadine has at least a 40 percent chance of successfully meeting that endpoint and that the study should be continued to completion. DOV intends to release unblinded results from this pivotal Phase III trial in the second quarter of 2006.